Indapamide in hypertension: results of a French multi-centre study in ambulant subjects.
The antihypertensive effect of indapamide (2.5 mg/day) was evaluated in 2184 patients with essential hypertension by 300 French general practitioners over a period of treatment of 3 months. Indapamide produced a significant reduction in blood pressure, the amplitude of which was directly related to pre-treatment blood pressure levels; normalization of blood pressure was achieved in approximately 66% of patients. Addition of a beta-blocker to the treatment regimen on the second month was required in only 10% of patients. No severe side-effect was reported, although a significant reduction in kalaemia was noted in less than 5% of patients.
D000368:Aged; D000553:Ambulatory Care; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007190:Indapamide / Q000627:therapeutic use*; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D004232:Diuretics; D014527:Uric Acid; D014508:Urea; D007190:Indapamide; D011188:Potassium